{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreiblrzykpttcrgkiiavsm4ijjixyiqksnn4drppb5ruhc2eyxgjcda",
    "uri": "at://did:plc:2gbt2dlwaqovtnmxkat3tyke/app.bsky.feed.post/3mepqganvcpx2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreiajn4u353n4sqhr7wufmvvki7pqvjc426uqivfj55kve5vnbc2pvy"
    },
    "mimeType": "image/jpeg",
    "size": 136194
  },
  "path": "/articles/d41586-026-00228-1",
  "publishedAt": "2026-02-13T05:08:27.066Z",
  "site": "https://www.nature.com",
  "tags": [
    "doi:10.1038/d41586-026-00228-1"
  ],
  "textContent": "Nature, Published online: 12 February 2026; doi:10.1038/d41586-026-00228-1\n\nA single class of drugs is changing how people think about weight, health and medicine.",
  "title": "The ‘astounding’ rise of semaglutide — and what’s next for weight-loss drugs",
  "updatedAt": "2026-02-12T00:00:00.000Z"
}